Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
AssigneesInstitut Pasteur, Institut National de la Sante et de la Recherche Medicale
InventorsPhilippe Sansonetti, Stephen Girardin, Dana Philpott, Ivo Boneca
Life of this patent
Estimating the term…
Abstract
A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.
Claims15
A method for enhancing an immune response of a host, which comprises administering to the host an antigen and a composition comprising a biologically acceptable carrier and a molecule selected from (i) GlcNAc-MurNAc-L-Ala-D-Glu-mesoDAP (MTP);
- (ii) MurNAc-L-Ala-D-Glu-mesoDAP;
- (iii) L-Ala-D-Glu-mesoDAP;
- and (iv) the molecule in which the L-Ala of (i), (ii), or (iii) is replaced with D-Ala, wherein the molecule is administered to the host in an amount sufficient to enhance the immune response.
A method for inducing an immune response in a host, which comprises administering to the host a composition comprising an antigen and an adjuvant, wherein the adjuvant comprises a tripeptide having the structure L-Ala-D-Glu-mesoDAP or D-Ala-D-Glu-mesoDap and wherein the amino acid Ala of said tripeptide is not linked to a N-acylmuramic acid.
A method of vaccination in a human or animal host comprising administering to the host a composition comprising an antigen and an adjuvant, wherein the adjuvant comprises a tripeptide having the structure L-Ala-D-Glu-mesoDAP or D-Ala-D-Glu-mesoDap and wherein the amino acid Ala of said tripeptide is not linked to a N-acylmuramic acid.
Dependencies are inferred from the claim text.